Cargando…

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

Co-administration of a long-acting β(2)-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matera, Maria Gabriella, Sanduzzi, Alessandro, Cazzola, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708173/
https://www.ncbi.nlm.nih.gov/pubmed/26792987
http://dx.doi.org/10.2147/COPD.S78000
_version_ 1782409415078445056
author Matera, Maria Gabriella
Sanduzzi, Alessandro
Cazzola, Mario
author_facet Matera, Maria Gabriella
Sanduzzi, Alessandro
Cazzola, Mario
author_sort Matera, Maria Gabriella
collection PubMed
description Co-administration of a long-acting β(2)-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β(2)-agonist fixed-dose combination that has been studied for this therapeutic indication.
format Online
Article
Text
id pubmed-4708173
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47081732016-01-20 Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease Matera, Maria Gabriella Sanduzzi, Alessandro Cazzola, Mario Int J Chron Obstruct Pulmon Dis Review Co-administration of a long-acting β(2)-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β(2)-agonist fixed-dose combination that has been studied for this therapeutic indication. Dove Medical Press 2016-01-05 /pmc/articles/PMC4708173/ /pubmed/26792987 http://dx.doi.org/10.2147/COPD.S78000 Text en © 2016 Matera et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Matera, Maria Gabriella
Sanduzzi, Alessandro
Cazzola, Mario
Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title_full Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title_fullStr Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title_full_unstemmed Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title_short Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
title_sort specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708173/
https://www.ncbi.nlm.nih.gov/pubmed/26792987
http://dx.doi.org/10.2147/COPD.S78000
work_keys_str_mv AT materamariagabriella specificroleofcombinationaclidiniumformoterolinthetreatmentofchronicobstructivepulmonarydisease
AT sanduzzialessandro specificroleofcombinationaclidiniumformoterolinthetreatmentofchronicobstructivepulmonarydisease
AT cazzolamario specificroleofcombinationaclidiniumformoterolinthetreatmentofchronicobstructivepulmonarydisease